{"id":18436,"date":"2025-10-23T15:22:57","date_gmt":"2025-10-23T08:22:57","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=18436"},"modified":"2025-10-23T15:22:57","modified_gmt":"2025-10-23T08:22:57","slug":"metformin-oral-solution","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/metformin-oral-solution\/","title":{"rendered":"Metformin Oral Solution"},"content":{"rendered":"<p>Edition: BP 2025 (Ph. Eur. 11.6 update)<\/p>\n<p><strong>Action and use<\/strong><\/p>\n<p>Biguanide; treatment of diabetes mellitus.<\/p>\n<h2>DEFINITION<\/h2>\n<p>Metformin Oral Solution is a solution of Metformin Hydrochloride in a suitable flavoured vehicle.<\/p>\n<p><em>The oral solution complies with the requirements stated under Oral Liquids and with the following requirements.<\/em><\/p>\n<p><strong>Content of metformin hydrochloride, C<sub>4<\/sub>H<sub>11<\/sub>N<sub>5<\/sub>,HCl<\/strong><\/p>\n<p>95.0 to 105.0% of the stated amount.<\/p>\n<h2>IDENTIFICATION<\/h2>\n<p>In the Assay, record the UV spectrum of the principal peak in the chromatograms obtained with solutions (1) and (2) with a diode array detector in the range of 190 to 400 nm.<\/p>\n<p>The UV spectrum of the principal peak in the chromatogram obtained with solution (1) is concordant with that of the peak in the chromatogram obtained with solution (2);<br \/>\nthe retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that of the peak in the chromatogram obtained with solution (2).<\/p>\n<h2>TESTS<\/h2>\n<p><strong>Related substances<\/strong><\/p>\n<p>Carry out the method for liquid chromatography, Appendix III D, using the following solutions.<\/p>\n<p>(1) Dilute the oral solution with methanol (40%) to produce a solution containing 0.5% w\/v of Metformin Hydrochloride and further dilute 1 volume of this solution to 10 volumes with mobile phase. Filter using a 0.45-\u00b5m PTFE or nylon filter if necessary.<\/p>\n<p>(2) Dilute 1 volume of solution (1) to 100 volumes with the mobile phase and dilute 1 volume of the resulting solution to 10 volumes with the mobile phase.<\/p>\n<p>(3) 0.00001% w\/v of metformin impurity A EPCRS (1-cyanoguanidine) in the mobile phase.<\/p>\n<p>(4) 0.05% w\/v of metformin for system suitability BPCRS in the mobile phase.<\/p>\n<h3>CHROMATOGRAPHIC CONDITIONS<\/h3>\n<p>(a) Use a stainless steel column (15 cm \u00d7 4.6 mm) packed with end-capped dodecylsilyl silica gel for chromatography (4 \u00b5m) (Phenomenex Synergi RP Max-RP is suitable).<\/p>\n<p>(b) Use isocratic elution and the mobile phase described below.<\/p>\n<p>(c) Use a flow rate of 1.0 mL per minute.<\/p>\n<p>(d) Use a column temperature of 35\u00b0.<\/p>\n<p>(e) Use a detection wavelength of 218 nm.<\/p>\n<p>(f) Inject 10 \u00b5L of each solution.<\/p>\n<h3>MOBILE PHASE<\/h3>\n<p>42 volumes of methanol R2 and 58 volumes of a buffer solution containing 0.125% w\/v of sodium dodecyl sulfate, 1% v\/v of triethylamine and 1.46% w\/v of orthophosphoric acid adjusted to pH 3.15 with sodium hydroxide.<\/p>\n<p>When the chromatograms are recorded under the prescribed conditions, the relative retentions with reference to metformin (retention time about 10 minutes) are: impurity A, about 0.2; impurity D, about 0.5; impurity 1, about 1.1.<\/p>\n<h3>SYSTEM SUITABILITY<\/h3>\n<p>The test is not valid unless, in the chromatogram obtained with solution (4), the resolution between the peaks due to methylhydroxybenzoate and metformin hydrochloride is at least 1.5 and the resolution between the peaks due to metformin hydrochloride and metformin impurity 1 is at least 2.0.<\/p>\n<h3>LIMITS<\/h3>\n<p>In the chromatogram obtained with solution (1):<\/p>\n<p>the area of any peak corresponding to impurity 1 is not greater than three times the area of the principal peak in the chromatogram obtained with solution (2) (0.3%);<\/p>\n<p>the area of any peak corresponding to metformin impurity A (1-cyanoguanidine) is not greater than the area of the principal peak in the chromatogram obtained with solution (3) (0.02%);<\/p>\n<p>the area of any other secondary peak is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.10%);<\/p>\n<p>the sum of the areas of all secondary peaks, except those due to metformin impurity A (1-cyanoguanidine) and metformin impurity 1, is not greater than four times the area of the principal peak in the chromatogram obtained with solution (2) (0.4%);<\/p>\n<p>Disregard any peak, except that due to metformin impurity A (1-cyanoguanidine), with an area less than half the area of the principal peak in the chromatogram obtained with solution (2) (0.05%).<\/p>\n<h2>ASSAY<\/h2>\n<p>Carry out the method for liquid chromatography, Appendix III D, using the following solutions.<\/p>\n<p>Solution A: 1.7% w\/v of ammonium dihydrogen orthophosphate adjusted to pH 3.0 with orthophosphoric acid. Solution B:\u00a0 1 volume of acetonitrile R1 and 19 volumes of 0.1% v\/v of orthophosphoric acid.<\/p>\n<p>(1) Dilute a weighed quantity of the oral solution with sufficient volume of solution A to produce a solution containing 0.1% w\/v of Metformin Hydrochloride and filter through a 0.45-\u00b5m nylon filter, if necessary. Dilute 1 volume of the resulting solution to 10 volumes with solution B.<\/p>\n<p>(2) 0.01% w\/v of metformin hydrochloride BPCRS in solution B.<\/p>\n<h3>CHROMATOGRAPHIC CONDITIONS<\/h3>\n<p>(a) Use a stainless steel column (5 cm \u00d7 4.6 mm) packed with strong cation-exchange silica gel for chromatography (5\u00b5m) (Phenomenex Luna SCX is suitable).<\/p>\n<p>(b) Use isocratic elution and the mobile phase described below.<\/p>\n<p>(c) Use a flow rate of 2 mL per minute.<\/p>\n<p>(d) Use a column temperature of 30\u00b0.<\/p>\n<p>(e) Use a detection wavelength of 205 nm.<\/p>\n<p>(f) Inject 20 \u00b5L of each solution.<\/p>\n<h3>MOBILE PHASE<\/h3>\n<p>16 volumes of acetonitrile R1 and 84 volumes of 0.05M potassium dihydrogen orthophosphate, previously adjusted to pH 3.5 with orthophosphoric acid .<\/p>\n<p>When the chromatograms are recorded under the prescribed conditions, the retention time of metformin is about 3 minutes.<\/p>\n<h3>DETERMINATION OF CONTENT<\/h3>\n<p>Determine the weight per mL of the oral solution, Appendix V G, and calculate the content of C<sub>4<\/sub>H<sub>11<\/sub>N<sub>5<\/sub>,HCl, weight in volume, using the declared content of C<sub>4<\/sub>H<sub>11<\/sub>N<sub>5<\/sub>,HCl in metformin hydrochloride BPCRS.<\/p>\n<h2>IMPURITIES<\/h2>\n<p>The impurities limited by the requirements of this monograph include impurities A and D listed under Metformin Hydrochloride and:<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-18442\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Metformin-Oral-Solution-British-Pharmacopoeia-2025-2.jpg\" alt=\"Metformin Oral Solution\" width=\"1200\" height=\"650\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Metformin-Oral-Solution-British-Pharmacopoeia-2025-2.jpg 1200w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Metformin-Oral-Solution-British-Pharmacopoeia-2025-2-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Metformin-Oral-Solution-British-Pharmacopoeia-2025-2-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Metformin-Oral-Solution-British-Pharmacopoeia-2025-2-768x416.jpg 768w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/><\/p>\n<p>1. N\u2032-(Aminoiminomethyl)-N,N-dimethylurea<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Biguanide; treatment of diabetes mellitus. DEFINITION Metformin Oral Solution is a solution of Metformin Hydrochloride in a suitable flavoured vehicle. The oral solution complies with the requirements stated under Oral Liquids and with the following requirements. Content of metformin hydrochloride, C4H11N5,HCl 95.0 to 105.0% of&#8230;<\/p>\n","protected":false},"author":5,"featured_media":18439,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-18436","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/18436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=18436"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/18436\/revisions"}],"predecessor-version":[{"id":18449,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/18436\/revisions\/18449"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/18439"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=18436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=18436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=18436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}